Every patient with ADHD is different
Patients' response to medications can vary.
With DYANAVEL® XR, drug release is not affected by food timing or type, amphetamine metabolism, location of release in the GI tract, or pH of the GI tract.1, 2
Unique technology provides all-day efficacy3
Continuous amphetamine release for predictable symptom control from patient to patient through the day3,4
Consistent PK profile with no additional peak or crash2
13-hour postdose duration of efficacy with no return to baseline
Liquid formulation that allows for titration in 1 prescription
ADHD, Attention Deficit Hyperactivity Disorder; PK, pharmacokinetic.
References: 1. Pardo A, Kando JC, King TR, Rafla E, Herman BK. Single-dose pharmacokinetics of amphetamine extended-release tablets compared with amphetamine extended-release oral suspension. CNS Spectr. 2020;25(6):774-781. 2. Herman BK, King TR, Kando JC, et al. A novel, modified release drug delivery technology (LiquiXR®) containing amphetamine ion-exchange complexes. Poster presented at: Psych Congress; October 3-6, 2019. San Diego, CA. 3. Cutler AJ, Pardo A, King TR, et al. Randomized, double-blind, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of the amphetamine extended-release tablet in adults with attention-deficit/hyperactivity disorder. Poster presented at 2021 APSARD; January 15-17. 4. Childress AC, Wigal SB, Brams MN, et al. Efficacy and safety of amphetamine extended-release oral suspension in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psycholpharmacol. 2018;28(5):306-313.